Differential Paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3339-3345

  Lui, Wing Yiu ^a,b   Chang, Yuh Fang ^b   Li, Li Lydia ^b   Ho, Li Kang ^a   Su, Teh Lih ^b   Chen, Jeou Yuan ^c   Liu, Tsung Yun ^a,b   P'Eng, Fang Ku ^a,b   Chi, Chin Wen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Apoptosis; Cell cycle; Cytotoxicity; Drug resistance; Hepatoma; p53; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; PACLITAXEL;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CELL CYCLE G2 PHASE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HEPATOMA CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; RAT; TAIWAN; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DNA FRAGMENTATION; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, P53; HUMANS; LIVER NEOPLASMS; MICE; PACLITAXEL; RATS; TUMOR CELLS, CULTURED;

EID: 0031729898     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Health statistics of the Republic of China. Vital Statistics, pp 42-59, Taipei, Taiwan, R. O. C., 1987.
2. Philips R and Murikami K: Primary neoplasms of the liver. Results of radiation therapy. Cancer 13: 714-720, 1960.
3. Cocharne AMG, Murray-Lyon IM, Brinkley DM and Illiams R: Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 40: 609-614, 1977.
4. Sheen MC, Huang TJ, Sheen PC, Ho YH, Sheu HM, Ou SC, Chen CY and Wu CC: Continuous intraarterial infusion chemotherapy of hepatoma. J Formosan Med Assoc 82: 389-398, 1983.
5. Bern MM, McDermott W Jr, Cady B, Oberfield RA, Trey C, Clouse ME, Tullis JL and Parker LM: Intraarterial hepatic infusion and intravenous adriamycin for treatmet of hepatocellular carcinoma: A clinical and pharmacology report. Cancer 43: 399-405, 1978.
6. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem. Soc 93: 2325-2327, 1971.
7. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
8. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci 77: 1561-1565, 1980.
9. Paull KD, Lin CM, Malspeis L and Hamel E: Identification of novel antimitotic agents acting at the tubulin level by computer assisted evaluation of differential cytotoxicity data. Cancer Res 52: 3892-3900, 1992.
10. Tishler RB, Geard CR, Hall EJ and Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497, 1992.
11. Chang Y-F, Li L-L, Wu C-W, Liu T-Y, Lui W-Y, P'eng F-K and Chi C-W: Paclitaxel-induced apoptosis in human gastric cancer cell lines. Cancer 77: 14-18, 1996.
12. Stearns ME and Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3ML) invasion and metastasis. Cancer Res 52: 3776-3781, 1992.
13. Speicher LA, Barone L and Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52: 4433-4440, 1992.
14. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
15. Legha SS, Ring SP, Papadopoulos N, Raber M and Benjamin RS: A phase II trial of taxol in metastatic melanoma. Cancer 65: 2478-2481, 1990.
16. Einzig AI, Wernik P, Sasloff J, Garl S, Runowicz C, O'Hanlan KA and Goldberg G: Phase II study of taxol in patients with advanced ovarian cancer. Proc Am Soc Cancer Res 31: 1114, 1990.
17. Jaskulski D, deReil JK, Mercer WE, Calabretta B and Baserga R: Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 240: 1544-1546, 1988.
18. Prelich G, Kostura M, Marshak DR, Mathews MB and Stillman B: The cell cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature 326: 471-475, 1987.
19. Toschi L and Bravo R: Changes in cyclin proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol 107: 1623-1628, 1988.
20. Celis JE and Madsen P: Increased nuclear cyclin/PCNA antigen staining of non S-phase transformed human amnion cells engaged in nucleotide excision DNA repair. FEBS Lett 209: 277-283, 1986.
21. Shivji KK, Kenny MK and Wood RD: Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69: 367-374, 1992.
22. Waga S, Hannon GJ, Bearh D and Shillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
23. El-Deiry WS, Tokino T, Velculescu VE. Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF-1, a potential mediator of p53 tumor suppresion. Cell 75: 817-825, 1993.
24. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 74: 957-967, 1993.
25. Sheu JC, Huang GT, Lee PH, Chung JC, Chou HC, Lai MY, Wang JT, Lee HS, Shin LN, Yang PM, Wang TH and Chen DS: Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 52: 6098-6100, 1992.
26. Farshid M and Tabor E: Expression of oncogenes and tumor suppressor genes in human hepatocellular carcinoma and hepatoblastoma cell lines. J Med Virol 38: 235-239, 1992.
27. Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B Surface antigen. Science (Wash.DC) 209: 497-499, 1980.
28. Chang C, Hu CP, Tang T, Chou CF, Ting LP and Chou CK: The differentiation properties of human hepatoma cell lines. In Molecular biology of neoplasia. Chan EH, Lin JK and Huang PC (ed). Taipei, Academia Sinica, 1985, pp 262-269.
29. Landberg G and Roos G: Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis. Cancer Res 51: 4570-4574, 1991.
30. Subramanian T, Tarodi B and Chinnadurai G: p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: suppression by E1B 19K and Bcl-2 proteins. Cell Growth Differ 6: 131-137, 1995.
31. Chen JY, Funk WD, Wright WE, Shay JW and Minna JD: Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8: 2159-2166, 1993.
32. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68: 1104-1109, 1993.
33. Huang C, Wu M, Xu G, Li D, Cheng H, Tu Z, Jiang H and Gu J: Overexpression of the MDR 1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84: 262-264, 1992.
34. Roberts JR, Allison DC, Donehower RC and Rowinsky EK: Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 50: 710-716, 1990.
35. Rowinsky EK and Donehower RC: Paclitaxel (Taxol). New Eng J Med 332: 1004-1014, 1995.
36. Colombel M, Olsson CA, Ng PY and Buttyan R: Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 52: 4313-4319, 1992.
37. cdc2 incident with taxol-induced apoptosis. Cell Growth Differ 5: 1041-1050, 1994.
38. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, William Demers G and Galloway DA: Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79, 1996.